公开(公告)号：US08383793B2

公开(公告)日：2013-02-26

申请号：US12761050

申请日：2010-04-15

申请人： Stephan W. Morris ,  Qin Jiang ,  Xiaoli Cui ,  Liquan Xue

发明人： Stephan W. Morris ,  Qin Jiang ,  Xiaoli Cui ,  Liquan Xue

IPC分类号： C07H21/04 ,  C12N15/00

CPC分类号： C12Q1/6886 ,  C07K14/71 ,  C12N9/12 ,  C12Q1/485 ,  C12Q2600/156 ,  G01N33/574

摘要： Compositions and methods for the diagnosis and treatment of a cancer that is resistant to at least one anaplastic lymphoma kinase (ALK) kinase inhibitor are provided herein. The present invention is based on the discovery of mutations within ALK that confer resistance to at least one ALK kinase inhibitor. Polynucleotides and polypeptides having at least one ALK inhibitor resistance mutation are provided and find use in methods and compositions useful in the diagnosis, prognosis, and/or treatment of diseases associated with aberrant ALK activity, more particularly, those that are resistant to at least one ALK kinase inhibitors. Methods and compositions are also provided for the identification of agents that can inhibit the kinase activity and/or reduce the expression level of the ALK resistance mutants.

摘要翻译： 本文提供了用于诊断和治疗对至少一种间变性淋巴瘤激酶（ALK）激酶抑制剂有抗性的癌症的组合物和方法。 本发明基于ALK中突变的发现，其赋予对至少一种ALK激酶抑制剂的抗性。 提供具有至少一种ALK抑制剂抗性突变的多核苷酸和多肽，并且可用于有助于诊断，预后和/或治疗与异常ALK活性相关的疾病的方法和组合物，更具体地，可用于至少一种 ALK激酶抑制剂。 还提供了用于鉴定可以抑制激酶活性和/或降低ALK抗性突变体的表达水平的试剂的方法和组合物。

公开(公告)号：US20110256546A1

公开(公告)日：2011-10-20

申请号：US12761050

申请日：2010-04-15

申请人： STEPHAN W. MORRIS ,  QIN JIANG ,  Xiaoli Cui ,  Liquan Xue

发明人： STEPHAN W. MORRIS ,  QIN JIANG ,  Xiaoli Cui ,  Liquan Xue

IPC分类号： C12Q1/68 ,  C12N15/63 ,  C12N5/10 ,  C07H21/04

CPC分类号： C12Q1/6886 ,  C07K14/71 ,  C12N9/12 ,  C12Q1/485 ,  C12Q2600/156 ,  G01N33/574

摘要： Compositions and methods for the diagnosis and treatment of a cancer that is resistant to at least one anaplastic lymphoma kinase (ALK) kinase inhibitor are provided herein. The present invention is based on the discovery of mutations within ALK that confer resistance to at least one ALK kinase inhibitor. Polynucleotides and polypeptides having at least one ALK inhibitor resistance mutation are provided and find use in methods and compositions useful in the diagnosis, prognosis, and/or treatment of diseases associated with aberrant ALK activity, more particularly, those that are resistant to at least one ALK kinase inhibitors. Methods and compositions are also provided for the identification of agents that can inhibit the kinase activity and/or reduce the expression level of the ALK resistance mutants.

摘要翻译： 本文提供了用于诊断和治疗对至少一种间变性淋巴瘤激酶（ALK）激酶抑制剂有抗性的癌症的组合物和方法。 本发明基于ALK中突变的发现，其赋予对至少一种ALK激酶抑制剂的抗性。 提供具有至少一种ALK抑制剂抗性突变的多核苷酸和多肽，并且可用于有助于诊断，预后和/或治疗与异常ALK活性相关的疾病的方法和组合物，更具体地，可用于至少一种 ALK激酶抑制剂。 还提供了用于鉴定可以抑制激酶活性和/或降低ALK抗性突变体的表达水平的试剂的方法和组合物。

公开(公告)号：US20130244893A1

公开(公告)日：2013-09-19

申请号：US13771948

申请日：2013-02-20

申请人： Stephen W. Morris ,  Qin Jiang ,  Xiaoli Cui ,  Liquan Xue

发明人： Stephen W. Morris ,  Qin Jiang ,  Xiaoli Cui ,  Liquan Xue

IPC分类号： C12Q1/68 ,  C12N9/12

CPC分类号： C12Q1/6886 ,  C07K14/71 ,  C12N9/12 ,  C12Q1/485 ,  C12Q2600/156 ,  G01N33/574

摘要： Compositions and methods for the diagnosis and treatment of a cancer that is resistant to at least one anaplastic lymphoma kinase (ALK) kinase inhibitor are provided herein. The present invention is based on the discovery of mutations within ALK that confer resistance to at least one ALK kinase inhibitor. Polynucleotides and polypeptides having at least one ALK inhibitor resistance mutation are provided and find use in methods and compositions useful in the diagnosis, prognosis, and/or treatment of diseases associated with aberrant ALK activity, more particularly, those that are resistant to at least one ALK kinase inhibitors. Methods and compositions are also provided for the identification of agents that can inhibit the kinase activity and/or reduce the expression level of the ALK resistance mutants.

摘要翻译： 本文提供了用于诊断和治疗对至少一种间变性淋巴瘤激酶（ALK）激酶抑制剂有抗性的癌症的组合物和方法。 本发明基于ALK中突变的发现，其赋予对至少一种ALK激酶抑制剂的抗性。 提供具有至少一种ALK抑制剂抗性突变的多核苷酸和多肽，并且可用于有助于诊断，预后和/或治疗与异常ALK活性相关的疾病的方法和组合物，更具体地，可用于至少一种 ALK激酶抑制剂。 还提供了用于鉴定可以抑制激酶活性和/或降低ALK抗性突变体的表达水平的试剂的方法和组合物。